A Phase 2 Study of the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma

A Partially Masked, Phase 2 Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension (OH) or Open-Angle Glaucoma (OAG)

Status

Withdrawn

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00855517

Enrollment

Registered

2009-03-04

Start date

2009-03-31

Completion date

2009-07-31

Last updated

2013-09-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma, Ocular Hypertension

Brief summary

The purpose of this study is to evaluate IOP response to experimental dose of Latanoprost- PPDS in subjects with ocular hypertension or open-angle glaucoma.

Interventions

DRUGLatanoprost-PPDS

Control of IOP compared to baseline for the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Over 18 yrs of age with ocular hypertension or open-angle glaucoma * Subjects who have a best corrected visual acuity of 20/100 or better

Exclusion criteria

* Subjects who wear contact lenses. * Uncontrolled medical conditions * Subjects requiring chronic topical artifical tears, lubricants and/or requiring any other chronic topical medications * Subjects who have a history of chronic or recurrent inflammatory eye disease

Design outcomes

Primary

Measure	Time frame
IOP change from baseline	6 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026